AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35493937 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS (stDCS) + Working Memory Training (WMT)
Number of subjects: 54
Study 35493937 — intervention group
Group type: COMPARATOR
Intervention: Double-sham
Number of subjects: 54
Study 34183579 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus GG and a combination probiotic: L. rhamnosus and L. helveticus)
Number of subjects: 1770
Study 34183579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1770
Study 34183579 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 1770
Study 35674861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab monotherapy
Number of subjects: 0
Study 35674861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab with methotrexate (MTX)
Number of subjects: 0
Study 35674861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab with any csDMARD (including MTX)
Number of subjects: 0
Study 35674861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab with MTX
Number of subjects: 0
Study 34219510 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach training plus usual care
Number of subjects: 38
Study 34219510 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 38
Study 32127191 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 0
Study 34738687 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-tabac application
Number of subjects: 5293
Study 34738687 — intervention group
Group type: COMPARATOR
Intervention: Control application
Number of subjects: 5293
Study 33765581 — intervention group
Group type: EXPERIMENTAL
Intervention: EAE food supplement (500 mg daily for 6 months)
Number of subjects: 128
Study 33765581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 35980787 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 74
Study 35980787 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 74
Study 34529781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous loop diuretics
Number of subjects: 285
Study 34529781 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-driven intensified diuretic therapies (n = 43)
Number of subjects: 285
Study 34529781 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic-induced natriuresis
Number of subjects: 285
Study 34529781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diuretic urine sodium to creatinine ratio
Number of subjects: 285
Study 35113639 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Therapy (EFT)
Number of subjects: 58
Study 35113639 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 58
Study 33051759 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced laparoscopic curriculum (ALC) training
Number of subjects: 25
Study 33051759 — intervention group
Group type: COMPARATOR
Intervention: FLS training (control group)
Number of subjects: 25
Study 33971933 — intervention group
Group type: EXPERIMENTAL
Intervention: Add‐Aspirin trial with EHR data from NCRAS
Number of subjects: 0
Study 33971933 — intervention group
Group type: EXPERIMENTAL
Intervention: PATCH trial with EHR data from NICOR
Number of subjects: 0
Study 33971933 — intervention group
Group type: EXPERIMENTAL
Intervention: PATCH trial with EHR data from NHS Digital
Number of subjects: 0
Study 35796209 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 35796209 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and hs-cTnT
Number of subjects: 0
Study 35796209 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model
Number of subjects: 0
Study 35796209 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model for HF hospitalization
Number of subjects: 0
Study 35796209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality risk model
Number of subjects: 0
Study 35796209 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of risk models
Number of subjects: 0
Study 33772443 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISE model (with ECG)
Number of subjects: 1658
Study 33772443 — intervention group
Group type: COMPARATOR
Intervention: Duke Clinical Score (DCS)
Number of subjects: 1658
Study 33772443 — intervention group
Group type: COMPARATOR
Intervention: CAD Consortium Score (CCS-basic)
Number of subjects: 1658
Study 33772443 — intervention group
Group type: COMPARATOR
Intervention: CAD Consortium Score (CCS-clinical)
Number of subjects: 1658
Study 33772443 — intervention group
Group type: COMPARATOR
Intervention: Marburg Heart Score (MHS)
Number of subjects: 1658
Study 32710304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group (surfactant based on LUS score and/or FiO2 threshold)
Number of subjects: 56
Study 32710304 — intervention group
Group type: COMPARATOR
Intervention: Control group (guided by FiO2 only)
Number of subjects: 56
Study 35365511 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (open reduction and internal fixation)
Number of subjects: 154
Study 35365511 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (closed reduction followed by cast treatment)
Number of subjects: 154
Study 33236211 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestive lymphatic treatment (DLT) consisting of an intensive treatment phase of 3 weeks, followed by a maintenance treatment phase of 6 months.
Number of subjects: 194
Study 36463113 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia Master
Number of subjects: 125
Study 36463113 — intervention group
Group type: COMPARATOR
Intervention: IOLMaster 500
Number of subjects: 125
Study 36463113 — intervention group
Group type: COMPARATOR
Intervention: IOLMaster 700
Number of subjects: 125
Study 36463113 — intervention group
Group type: COMPARATOR
Intervention: Manifest refraction
Number of subjects: 125
Study 37873691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring autograft
Number of subjects: 100
Study 37873691 — intervention group
Group type: COMPARATOR
Intervention: Posterior tibialis allograft
Number of subjects: 100
Study 37873691 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall average tibial slope of nonfailure cohort
Number of subjects: 100
Study 37873691 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall average tibial slope of failure cohort
Number of subjects: 100
Study 37873691 — intervention group
Group type: EXPERIMENTAL
Intervention: Average slope of allograft failures
Number of subjects: 100
Study 37873691 — intervention group
Group type: EXPERIMENTAL
Intervention: Average slope of autograft failures
Number of subjects: 100
Study 34105695 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A) injections
Number of subjects: 54
Study 34105695 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 54
Study 34105695 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (SS)
Number of subjects: 54
Study 32343963 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 98
Study 32343963 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (control group)
Number of subjects: 98
Study 32744951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramics intervention
Number of subjects: 0
Study 32744951 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling intervention
Number of subjects: 0
Study 32744951 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait 12 weeks)
Number of subjects: 0
Study 32443744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group (PG, n = 55)
Number of subjects: 110
Study 32443744 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 55)
Number of subjects: 110
Study 35513977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (experimental group)
Number of subjects: 46
Study 35513977 — intervention group
Group type: COMPARATOR
Intervention: Typical sleep (control group)
Number of subjects: 46
Study 33832641 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 172
Study 33832641 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate adherence
Number of subjects: 172
Study 33832641 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence
Number of subjects: 172
Study 35901188 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet (VHS)
Number of subjects: 424
Study 35901188 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy Inductions (EI)
Number of subjects: 424
Study 35901188 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Journalism (BJ)
Number of subjects: 424
Study 34422049 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with chemotherapy
Number of subjects: 74
Study 34422049 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 74
Study 34058423 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic negative-pressure wound therapy device
Number of subjects: 110
Study 34058423 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressing
Number of subjects: 110
Study 35312891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based patient education tool
Number of subjects: 229
Study 35312891 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study 32598060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing with the addition of a skin barrier film
Number of subjects: 185
Study 32598060 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing (control group)
Number of subjects: 185
Study 35160103 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for 28 days
Number of subjects: 124
Study 35160103 — intervention group
Group type: COMPARATOR
Intervention: No exercise intervention for 28 days (control)
Number of subjects: 124
Study 32338345 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose apalutamide 240 mg
Number of subjects: 68
Study 35317414 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ‐LNS (130 µg selenium/20 g)
Number of subjects: 0
Study 35317414 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN (130 µg selenium per capsule)
Number of subjects: 0
Study 35317414 — intervention group
Group type: EXPERIMENTAL
Intervention: IFA (iron and folic acid)
Number of subjects: 0
Study 35317414 — intervention group
Group type: COMPARATOR
Intervention: SQ‐LNS
Number of subjects: 0
Study 32771032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days)
Number of subjects: 470
Study 32771032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg orally twice a day for 5 days)
Number of subjects: 470
Study 32771032 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2‐5)
Number of subjects: 470
Study 32771032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Hydroxychloroquine and Oseltamivir
Number of subjects: 470
Study 32771032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Hydroxychloroquine and Azithromycin
Number of subjects: 470
Study 32771032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Oseltamivir and Azithromycin
Number of subjects: 470
Study 32771032 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug regimen (Hydroxychloroquine, Oseltamivir, and Azithromycin)
Number of subjects: 470
Study 35351329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal demand (reading aloud for 1 hour at 85-90 dB)
Number of subjects: 35
Study 35351329 — intervention group
Group type: COMPARATOR
Intervention: Control (no vocal demand tasks)
Number of subjects: 35
Study 35351329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal demand
Number of subjects: 35
Study 35351329 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 36123937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS) nursing intervention in laparotomy (Group A2, n=34)
Number of subjects: 130
Study 36123937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS) nursing intervention in laparoscopic surgery (Group B2, n=32)
Number of subjects: 130
Study 36123937 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing in laparotomy (Group A1, n=33)
Number of subjects: 130
Study 36123937 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing in laparoscopic surgery (Group B1, n=31)
Number of subjects: 130
Study 36123937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS) nursing intervention
Number of subjects: 130
Study 36123937 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous implementation of FTS and laparoscopic surgery
Number of subjects: 130
Study 34528576 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (maintenance therapy)
Number of subjects: 0
Study 34528576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 33124177 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctoplasty
Number of subjects: 775
Study 33124177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacrocystorhinostomy with retrograde intubation (R-DCR)
Number of subjects: 775
Study 33124177 — intervention group
Group type: EXPERIMENTAL
Intervention: R-DCR
Number of subjects: 775
Study 33124177 — intervention group
Group type: EXPERIMENTAL
Intervention: Trephination
Number of subjects: 775
Study 33124177 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocanalicular intubation
Number of subjects: 775
Study 33124177 — intervention group
Group type: EXPERIMENTAL
Intervention: Canaliculodacryocystorhinostomy (CDCR)
Number of subjects: 775
Study 33124177 — intervention group
Group type: COMPARATOR
Intervention: StopLoss Jones tubes (SLJT)
Number of subjects: 775
Study 33372679 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d resveratrol
Number of subjects: 52
Study 33372679 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 52
Study 35342036 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention (PPI)
Number of subjects: 84
Study 35342036 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 84
Study 35342036 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 84
Study 32070353 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning (SBML) via the Uncertainty Communication Education Module (UCEM), which includes a web-based interactive module and a smartphone-based game, followed by remote deliberate practice sessions.
Number of subjects: 0
Study 32070353 — intervention group
Group type: COMPARATOR
Intervention: Delayed receipt of the Uncertainty Communication Education Module (UCEM) after the second study visit.
Number of subjects: 0
Study 36403208 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy (PP)
Number of subjects: 50
Study 36403208 — intervention group
Group type: COMPARATOR
Intervention: Full Pulpotomy (FP)
Number of subjects: 50
Study 33797018 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded non-ventilated lumen during OLV
Number of subjects: 30
Study 33797018 — intervention group
Group type: COMPARATOR
Intervention: Open non-ventilated lumen during OLV (control group)
Number of subjects: 30
Study 33423824 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZP), doses 5–20 mg IV
Number of subjects: 40
Study 33423824 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX), infusion 2–7 mcg/kg/min
Number of subjects: 40
Study 33423824 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX)
Number of subjects: 40
Study 33540351 — intervention group
Group type: EXPERIMENTAL
Intervention: IG-1 (face-to-face)
Number of subjects: 245
Study 33540351 — intervention group
Group type: COMPARATOR
Intervention: CG (control group)
Number of subjects: 245
Study 35108604 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session behavioural intervention combining childbirth-related reminder cues with a visuospatial task
Number of subjects: 18
Study 35108604 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session behavioural intervention
Number of subjects: 18
Study 34282160 — intervention group
Group type: COMPARATOR
Intervention: Obstetric hemorrhage risk assessment tool (low-risk group)
Number of subjects: 56903
Study 34282160 — intervention group
Group type: COMPARATOR
Intervention: Obstetric hemorrhage risk assessment tool (medium-risk group)
Number of subjects: 56903
Study 34282160 — intervention group
Group type: COMPARATOR
Intervention: Obstetric hemorrhage risk assessment tool (high-risk group)
Number of subjects: 56903
Study 34282160 — intervention group
Group type: COMPARATOR
Intervention: Medium- and high-risk groups compared to low-risk group
Number of subjects: 56903
Study 34349013 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-mounted stent (BMS)
Number of subjects: 232
Study 32830552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 16
Study 32830552 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 16
Study 32560705 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-4 screening scale
Number of subjects: 2426
Study 36244275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 46
Study 36244275 — intervention group
Group type: COMPARATOR
Intervention: Sham Dry Needling (Sham-DN)
Number of subjects: 46
Study 32554198 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 2419
Study 32554198 — intervention group
Group type: COMPARATOR
Intervention: Open Surgical Repair (OSR)
Number of subjects: 2419
Study 36017782 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-day dexamethasone (DEX)
Number of subjects: 242
Study 36017782 — intervention group
Group type: COMPARATOR
Intervention: Multiple-day dexamethasone (DEX) plus palonosetron and NK-1 receptor antagonists (NK-1RAs)
Number of subjects: 242
Study 33940867 — intervention group
Group type: COMPARATOR
Intervention: Visual condition with a blank silhouette
Number of subjects: 0
Study 33940867 — intervention group
Group type: COMPARATOR
Intervention: Visual condition with a European face
Number of subjects: 0
Study 33940867 — intervention group
Group type: COMPARATOR
Intervention: Visual condition with an East Asian face
Number of subjects: 0
Study 33940867 — intervention group
Group type: COMPARATOR
Intervention: Visual condition with a South Asian face
Number of subjects: 0
Study 33940867 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-native accent perception
Number of subjects: 0
Study 33940867 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct perception of Chinese-accented speech
Number of subjects: 0
Study 35660990 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg/day
Number of subjects: 93
Study 35660990 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 1 mg/day
Number of subjects: 93
Study 35660990 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 50 mg/day
Number of subjects: 93
Study 33899642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) treatment
Number of subjects: 0
Study 32720618 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 40
Study 32720618 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous hypoglycemic therapy)
Number of subjects: 40
Study 36145177 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg choline/d
Number of subjects: 30
Study 36145177 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg choline/d
Number of subjects: 30
Study 36145177 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant maternal PEMT rs4646343 genotypes
Number of subjects: 30
Study 36145177 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant maternal MTHFD1 rs2235226 genotypes
Number of subjects: 30
Study 34303034 — intervention group
Group type: EXPERIMENTAL
Intervention: CARA breast support
Number of subjects: 30
Study 34303034 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 30
Study 33568556 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 381
Study 33568556 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at Week0, Week4, then Q8W
Number of subjects: 381
Study 33568556 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab (both Q4W and Q8W)
Number of subjects: 381
Study 33568556 — intervention group
Group type: COMPARATOR
Intervention: guselkumab Q4W
Number of subjects: 381
Study 33568556 — intervention group
Group type: COMPARATOR
Intervention: guselkumab Q8W
Number of subjects: 381
Study 33568556 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 381
Study 32501276 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle psychoeducational program (HLP)
Number of subjects: 221
Study 32501276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MP)
Number of subjects: 221
Study 32501276 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused program on positive affect promotion (PAPP)
Number of subjects: 221
Study 32501276 — intervention group
Group type: COMPARATOR
Intervention: Control condition (improved treatment as usual - iTAU)
Number of subjects: 221
Study 32501276 — intervention group
Group type: EXPERIMENTAL
Intervention: All low-intensity psychological interventions (HLP, MP, PAPP)
Number of subjects: 221
Study 32501276 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPP
Number of subjects: 221
Study 36171028 — intervention group
Group type: EXPERIMENTAL
Intervention: +Stay Active intervention (smartphone application combined with motivational interviewing)
Number of subjects: 60
Study 36171028 — intervention group
Group type: EXPERIMENTAL
Intervention: +Stay Active intervention
Number of subjects: 60
Study 34404467 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (anodal)
Number of subjects: 73
Study 34404467 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 73
Study 33871218 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg/day for 12 weeks)
Number of subjects: 71
Study 33871218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71